{"id":"W2792282698","doi":"10.1158/1538-7445.sabcs17-p5-21-03","title":"Abstract P5-21-03: Palbociclib (PAL) + letrozole (LET) as first-line therapy in estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC): Efficacy and safety updates with longer follow-up across patient subgroups","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta; BC Cancer Agency","funders":"","keywords":"Palbociclib; Medicine; Internal medicine; Population; Progression-free survival; Breast cancer; Estrogen receptor; Metastatic breast cancer; Letrozole; Clinical endpoint; Cancer; Gynecology; Gastroenterology; Oncology; Randomized controlled trial; Overall survival; Tamoxifen","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006690099,0.0004305571,0.0008777764,0.0002515024,0.0001857588,0.0005573119,0.00042791,0.0004863444,0.01115931],"category_scores_gemma":[0.0005236359,0.0001887094,0.0005834439,0.0002877759,0.0002977358,0.0004308523,0.0002624967,0.001436527,0.001365748],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005666545,"about_ca_system_score_gemma":0.0007954661,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004965682,"about_ca_topic_score_gemma":0.00174498,"domain_scores_codex":[0.9998162,0.00007873681,0.00001352659,0.00003426153,0.00002785624,0.00002945344],"domain_scores_gemma":[0.9997711,0.00003919814,0.00005534401,0.00001697968,0.00001986611,0.00009754905],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","study_design_scores_codex":[0.6910518,0.009457414,0.008649996,0.001235246,0.001226459,0.0001863695,0.0001376103,0.001195571,0.02749001,0.0004099258,0.01311755,0.2458421],"study_design_scores_gemma":[0.6105555,0.2917288,0.0593395,0.000184963,0.002420303,0.0006717958,0.0001166433,0.001963332,0.0109118,0.0006620353,0.02139837,0.0000469038],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"other","genre_scores_codex":[0.9801052,0.003822964,0.0006904036,0.0009361611,0.0001118742,0.001919543,0.004450823,0.0001551465,0.007807761],"genre_scores_gemma":[0.9861183,0.001457783,0.0009970554,0.0008858616,0.0001147437,0.00144048,0.003683525,0.00003128482,0.005270903],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.01115931,"threshold_uncertainty_score":0.03733158,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03254231058613841,"score_gpt":0.3694373333917152,"score_spread":0.3368950228055768,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}